Multiple myeloma (MM) is a B cell bone marrow neoplasia characterized by inflammation with an intense secretion of growth factors that promote tumor growth, cell survival, migration and invasion. Since, interactions between plasma cells, hematopoietic stem cells, bone marrow stromal cells and endothelial cells are intimately involved in all biological stages of intramedullary growth it is very important to analyze the in vitro-production of VEGF, from the separated cells from MM patients and to observe which cell types mostly contribute to this phenomenon. Column-based MACS® MicroBead Technology was used to obtained CD38possitive and CD38 negative cells from 5 ml of bone marrow of Multiple myeloma patients fulfilling the International Myeloma Working Group diagnostic criteria for active disease were studied. After separation on MACS magnetic sorter using Column-based MACS® Technology (Miltenyi Biotec) according manufacturer instructions, and after cell enumeration, 1.0 x 106 isolated CD38+ and CD38- cells, where then cultures in-vitro, in RPMI 1640 culture medium supplemented with 10% fetal calf serum following 24h. VEGF production was measured using eBioscience™ Human VEGF-A Platinum ELISA Kit. Results indicate that both cell type CD38 + and CD38- can produce VEGF after in-vitro cultures. Mean values of VEGF from CD38+ cells was 2.84 pg/ml while mean values from CD38- cells was 2.069 pg/ml (p> 0.05 Mann-Whitney U-test). No significant difference was found between production of VEGF from these two cell types. In addition, mean values of serum VEGF in this MM patients was 50.79 pg/ml. Bearing in mind that the mean value of isolated CD38 + cells from the bone marrow was on average about 3.0 x 106 cells and that the amount of CD38- cells was generally much more numerous, then it comes to the conclusion that the total produced amount of VEGF in MM certainly arises significantly from the population of stromal and all other cells that are not only CD38 +.